Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Ho: Ibalizumab for HIV Prevention |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Antibody Screening |
| Species: | Non-Organism Study |
| Stage: | Assays Completed |
| Study Start Date: | 2012-03-01 |
| Study Made Public: | 2013-02-13 |
Title
In vitro neutralization activity of ibalizumab and ibalizumab variants
Description
CAVD 353 is a monoclonal antibody characterization study to evaluate the neutralization activity of the monoclonal antibody, Ibalizumab, and Ibalizumab variants.
Sign in to see full information about this study and to download study data.
Products
No Products used in studyIntegrated data
NAb MAb
Non-integrated data
No non-integrated data is available for this study.